Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This entry refers to a combination therapy involving growth hormone and a gonadotropin-releasing hormone (GnRH) agonist. Growth hormone is a peptide hormone that stimulates growth, cell reproduction, and regeneration in humans. GnRH agonists are synthetic analogues of the natural hypothalamic neurohormone GnRH; they act as agonists at the gonadotropin-releasing hormone receptor on pituitary gonadotrophs, initially stimulating but then profoundly suppressing secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) through receptor desensitization[1][5][6]. This results in decreased production of sex steroids such as estrogen and testosterone. The combination is used clinically in certain pediatric endocrinology settings—for example, to optimize height outcomes in children with early puberty or specific growth disorders by delaying epiphyseal closure while promoting linear growth.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Growth hormone + gonadotropin-releasing hormone agonist.